Trial Profile
An Observational Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Herceptin, Perjeta in Combination With Herceptin, or Kadcyla During Pregnancy or Within 7 Months Prior to Conception
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 May 2019
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab emtansine (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Acronyms MotHER
- Sponsors Genentech
- 15 May 2019 Status changed from active, no longer recruiting to completed.
- 07 May 2019 Status changed from recruiting to active, no longer recruiting.
- 30 May 2017 Planned End Date changed from 1 Dec 2022 to 31 Jan 2025.